

Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men

Edwin O. Were^a, Renee Heffron^b, Nelly R. Mugo^{b,c,d,e},
Connie Celum^{b,f,g}, Andrew Mujugira^{b,g}, Elizabeth A. Bukusi^{b,c,h},
Jared M. Baeten^{b,f,g}, for the Partners PrEP Study Team*

Background: There is a paucity of data on the effect of antiretroviral medications on male fertility. Couples affected by HIV-1 often have fertility intentions, and antiretroviral medications, as both treatment of HIV-1-infected persons and pre-exposure prophylaxis (PrEP) for uninfected persons, are part of peri-conception risk reduction.

Methods: Within a randomized, placebo-controlled trial of daily oral tenofovir disoproxil fumarate (TDF) and combination emtricitabine (FTC)/TDF PrEP for HIV-1 prevention conducted among heterosexual HIV-1-serodiscordant couples, we assessed the impact of TDF and FTC/TDF use on male fertility, measured as incident pregnancy in female partners of men assigned to PrEP vs. placebo.

Results: Of the 2962 HIV-1-uninfected men partners, 986 were randomized to TDF, 1013 to FTC/TDF, and 963 to placebo. The overall pregnancy incidence in their HIV-1-infected female partners was 12.9 per 100 person-years and did not differ significantly across the study arms (13.2 TDF, 12.4 FTC/TDF, 13.2 placebo). The frequency of live births, pregnancy losses, and gestational age at birth or loss was also statistically similar in the three randomization groups.

Conclusion: TDF and FTC/TDF, when used as PrEP by HIV-1-uninfected men, did not adversely affect male fertility or pregnancy outcomes.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

AIDS 2014, **28**:1977–1982

Keywords: Africa, antiretroviral, HIV prevention, male fertility, pregnancy

Introduction

For heterosexual couples affected by HIV-1, a desire to have children is common, and strategies to reduce peri-conception HIV-1 transmission risk are needed [1,2].

Antiretroviral medications, as antiretroviral therapy (ART) for HIV-1-infected persons and as pre-exposure prophylaxis (PrEP) for HIV-1-uninfected persons, are potential components of a risk-reduction package for peri-conception use.

^aDepartment of Reproductive Health, Moi University, Eldoret, Kenya, ^bDepartment of Global Health, University of Washington, Seattle, Washington, USA, ^cCentre for Clinical Research, ^dCentre for Microbiology Research, Kenya Medical Research Institute, ^eDepartment of Obstetrics and Gynecology, Kenyatta National Hospital, Nairobi, Kenya, ^fDepartment of Medicine, ^gDepartment of Epidemiology, and ^hDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.

Correspondence to Jared Baeten, Department of Global Health, University of Washington, 325 Ninth Ave, Box 359927, Seattle, WA 98104, USA.

Tel: +1 206 520 3808; fax: +1 206 520 3831; e-mail: jbaeten@uw.edu

* Members of the Partners PrEP Study Team are listed in the Acknowledgements section.

Received: 14 February 2014; revised: 15 April 2014; accepted: 16 April 2014.

DOI:10.1097/QAD.0000000000000313

Only limited data are available on the effect of use of antiretroviral medications on sperm health and male fertility. Seminal quality studies conducted among HIV-1-infected men have suggested potential detrimental effects of some antiretroviral agents on seminal volume, sperm motility, and abnormal sperm morphology [3]; however, HIV-1 infection itself has also been associated with reduced seminal quality, including leucocytospermia and decreased sperm motility [4,5]. It is unclear if any potential effect of antiretroviral medications on seminal quality translates into a reduction in the capacity to father a child, as no studies have assessed the effect of antiretroviral medications directly on pregnancy incidence in female partners of men receiving vs. not receiving antiretroviral medications.

The antiretroviral agents tenofovir disoproxil fumarate (TDF) and combination emtricitabine (FTC)/TDF are commonly used as components of ART regimens and have been demonstrated to have efficacy for HIV-1 prevention as PrEP in clinical trials in diverse geographic settings [6–8]. TDF and FTC achieve high concentrations in genital tract secretions [9], but their effects on male fertility are unknown. The safety of PrEP is a key concern to potential users and, for many potential PrEP users, would encompass noninterference with reproductive intentions. In a clinical trial of PrEP among heterosexual HIV-1-uninfected African men and their HIV-1-infected female partners, we assessed pregnancy rates among partners of men receiving TDF and FTC/TDF PrEP compared with partners of men receiving placebo.

Methods

Population and procedures

Between July 2008 and November 2010, 4747 heterosexual HIV-1-serodiscordant couples were enrolled from nine sites in Kenya and Uganda in a phase III, randomized, double-blind, placebo-controlled trial of daily TDF and combination FTC/TDF PrEP for the prevention of HIV-1 acquisition (ClinicalTrials.gov number NCT00557245). The details of the study design, methods and primary results have been described elsewhere [6,10]. In brief, couples were eligible if they were sexually active and planned to remain in their relationship for the study period. HIV-1-uninfected members of the couple were required to have adequate renal, hepatic and hematological function, and not be infected with hepatitis B virus. HIV-1-infected members of the couple were not yet eligible for initiation of ART, as per the national guidelines at the time in Kenya and Uganda.

HIV-1-uninfected partners were assigned in a 1:1:1 ratio to one of the three study arms: TDF (300 mg), FTC/

TDF (200/300 mg), or placebo, taken once daily, and were followed monthly, with HIV-1 testing, provision of study medication, and adherence counseling. As reported previously, adherence was high, with more than 95% of dispensed pills estimated to have been taken, based on pill counts of returned unused study product, and more than 80% of a randomly selected subset of participants in the trial's active PrEP arms having study medication detected in plasma samples. Women (both HIV-1-uninfected and HIV-1-infected) were provided with contraception counseling and offered contraception on site at each study visit. HIV-1-infected partners were followed in parallel with their HIV-1-uninfected partners, with quarterly visits for clinical examinations and WHO staging, CD4⁺ cell counts every 6 months, and active referral to nearby HIV-1 care providers to initiate ART for those who became eligible for ART under national guidelines during follow-up.

HIV-1-infected women were offered urine pregnancy testing as indicated clinically; those who became pregnant were referred for prevention of mother-to-child transmission (PMTCT) services. Pregnancy data were recorded on standardized case report forms, with outcomes of pregnancies occurring in HIV-1-infected women assessed by participant report; infants were not followed.

All couples received a comprehensive package of HIV-1 prevention services, including individual and couple risk-reduction counseling, free condoms, and screening and treatment for sexually transmitted infections. The study received ethical approval from Institutional Review Boards at the University of Washington and the collaborating institutions for each study site. All participants provided written informed consent.

Data analysis

The present analysis was limited to couples in which the HIV-1-uninfected partner was male. The primary outcome was incident pregnancy among the HIV-1-infected female study partners of HIV-1-uninfected men; the primary exposure was trial randomization group (TDF, FTC/TDF, or placebo), analyzed as intention-to-treat. Data through July 2011 were included, when the trial demonstrated efficacy of TDF and FTC/TDF PrEP for HIV-1 prevention and the placebo arm was discontinued. Pregnancy incidence rates across randomization arms were compared using Cox proportional-hazards modeling. Chi-square tests were used to determine differences in pregnancy outcomes across the study arms. Finally, a number of demographic, sexual behavior, and medical characteristics were considered as potential correlates of pregnancy using multivariate analysis. SAS 9.3 was used for all analysis (SAS Institute Inc., Cary, North Carolina, USA).

Results

Of the 4747 HIV-1-serodiscordant couples enrolled and followed in the clinical trial, 2962 were couples in which

the HIV-1-uninfected partner was male: 986 randomized to TDF, 1013 to FTC/TDF, and 963 to placebo (Table 1). The median age of the male HIV-1-uninfected partners was 34 years [interquartile range (IQR) 29–41] and

Table 1. Enrollment characteristics and associations with pregnancy incidence.

	Prevalence at enrollment <i>N</i> (%)			Analysis of factors associated with pregnancy			
	TDF (<i>N</i> = 986)	FTC/TDF (<i>N</i> = 1013)	Placebo (<i>N</i> = 963)	Unadjusted HR (95% CI)	<i>P</i> -value	Multivariate ^b HR (95% CI)	<i>P</i> -value
Randomization arm							
TDF				0.99 (0.80–1.22)	0.91		
FTC/TDF				0.93 (0.75–1.14)	0.48		
Placebo				1.00			
Demographic characteristics							
Age (years)							
18–24	98 (9.94)	108 (10.66)	95 (9.87)	2.11 (1.61–2.76)	<0.001	2.32 (1.73–3.11)	<0.001
25–29	209 (21.20)	197 (19.45)	175 (18.17)	1.77 (1.41–2.21)	<0.001	1.76 (1.37–2.27)	<0.001
30–34	240 (24.34)	239 (23.59)	223 (23.16)	1.52 (1.23–1.89)	<0.001	1.60 (1.27–2.01)	<0.001
35+	439 (44.52)	469 (46.30)	470 (48.81)	1.00		1.00	
Married							
Yes	968 (98.17)	991 (97.83)	948 (98.44)	1.69 (0.74–3.84)	0.21		
Not married	18 (1.83)	22 (2.17)	15 (1.56)	1.00			
Children with study partner							
0	262 (26.57)	280 (27.64)	249 (25.86)	1.54 (1.26–1.88)	<0.001	0.88 (0.71–1.10)	0.27
1	231 (23.43)	241 (23.79)	258 (26.79)	1.38 (1.12–1.70)	0.002	1.05 (0.84–1.33)	0.65
≥2	493 (50.00)	492 (48.57)	456 (47.35)	1.00		1.00	
Earns income							
Yes	842 (85.40)	848 (83.71)	838 (87.02)	0.88 (0.70–1.10)	0.26		
No	144 (14.60)	165 (16.29)	125 (12.98)	1.00			
Number of alcoholic drinks in 1 week							
None	684 (69.37)	690 (68.11)	655 (68.02)	1.00		1.00	
1 drink	128 (12.98)	152 (15.00)	154 (15.99)	1.10 (0.87–1.37)	0.43	1.22 (0.97–1.54)	0.09
>1 drink	174 (17.65)	171 (16.88)	154 (15.99)	0.64 (0.49–0.83)	0.001	0.74 (0.57–0.97)	0.03
Behavioral characteristics							
Condom use with study partner, prior month ^a							
No sex	40 (4.06)	46 (4.54)	41 (4.26)	0.95 (0.73–1.26)	0.74	0.89 (0.68–1.18)	0.42
<100% condom use	301 (30.53)	295 (29.12)	265 (27.52)	3.26 (2.69–3.96)	<0.001	3.21 (2.63–3.92)	<0.001
100% condom use	645 (65.42)	672 (66.34)	657 (68.22)	1.00		1.00	
Sex with another partner, past month ^a							
Yes	146 (14.81)	134 (13.23)	118 (12.25)	0.99 (0.79–1.25)	0.96		
No	840 (85.19)	879 (86.77)	845 (87.75)	1.00			
Characteristics of HIV-1-infected female partner							
Age (years)							
18–24	258 (26.17)	276 (27.25)	260 (27.00)	5.75 (4.21–7.86)	<0.001		
25–29	277 (28.09)	257 (25.37)	235 (24.40)	3.92 (2.84–5.41)	<0.001		
30–34	215 (21.81)	225 (22.21)	216 (22.43)	2.90 (2.07–4.06)	<0.001		
≥35	236 (23.94)	255 (25.17)	252 (26.17)	1.00			
Use of any effective contraception (oral, injectable, implant, IUD, diaphragm, surgical vs. none) ^a	290 (29.41)	324 (31.98)	321 (33.33)	0.18 (0.14–0.22)	<0.001	0.17 (0.13–0.22)	<0.001
ART use (vs. none) ^{a,c}	0	0	0	0.74 (0.51–1.09)	0.13		
CD4 ⁺ cell count (cells/μl) ^a							
<250	0	0	0	1.21 (0.73–2.01)	0.45		
250–349	165 (16.73)	178 (17.57)	150 (15.58)	1.01 (0.68–1.51)	0.95		
350–500	299 (30.32)	278 (27.44)	277 (28.76)	1.18 (0.86–1.61)	0.31		
>500	522 (52.94)	557 (54.99)	536 (55.66)	1.00			
WHO stage ^a							
Stage 1–2	931 (94.42)	970 (95.76)	905 (93.98)	1.00			
Stage 3–4	55 (5.58)	43 (4.24)	58 (6.02)	1.08 (0.80–1.46)	0.60		

^aAnalyzed as a time-dependent factor in longitudinal analysis of factors associated with incident pregnancy. *N* (%) or median (IQR) are from the time of enrollment.

^bThe multivariate model includes all factors that were significantly associated with pregnancy (at a level of *P* < 0.05) in unadjusted analysis and not colinear with other factors.

^cAs part of trial eligibility criteria, women were not using ART at enrollment. Four hundred and forty-seven (15%) women initiated ART during study follow-up.

71.3% were less than 40 years of age. Nearly all (98.1%) were married to their HIV-1-infected partner, and 19.3% had an additional wife as well. Most (89.1%) had children and the majority (73.3%) had at least one child with their study partner. Two-thirds reported 100% condom use with their study partner during the month prior to enrollment. At enrollment, 31.6% of the HIV-1-infected women reported using an effective contraceptive method and effective contraception was reported at 49.8% of follow-up visits. HIV-1-infected female partners had a median age of 29 years (IQR 24–35) and a median CD4⁺ cell count of 527 cells/ μ l (IQR 395–704) at enrollment. Baseline characteristics were similar across the randomization arms.

Couples were followed for a median of 21 (IQR 15–27) months, with HIV-1-infected female partners contributing 4104 person-years of follow-up for assessment of incident pregnancy. A total of 583 pregnancies occurred during follow-up, for an overall pregnancy incidence of 12.9 [95% confidence interval (CI) 11.9–14.0] per 100 person-years (Table 2). Pregnancy incidence was similar across the study arms: 13.2 for couples in which the male partner had been assigned TDF (hazard ratio 0.99, $P=0.91$ vs. placebo), 12.4 for FTC/TDF (hazard ratio 0.93, $P=0.48$ vs. placebo), and 13.2 for placebo. The majority (78.9%) of pregnancies resulted in a live birth. The gestational age at the end of pregnancy, frequency of live births and pregnancy losses were similar across the study arms, with a slightly greater proportion of pregnancies ending in live birth in the FTC/TDF arm compared to placebo.

In the multivariate analysis, HIV-1-infected women were more likely to become pregnant if their male partner was younger [adjusted hazard ratio (aHR) 2.32 for men aged 18–24 years, aHR 1.76 for men aged 25–29 years, aHR

1.60 men aged 30–34 years vs. men ≥ 35 years]. The likelihood of pregnancy was marginally lower for men reporting more than one alcoholic drink per week (aHR 0.74, 95% CI 0.57–0.97). Less than 100% condom use and nonuse of effective contraception were associated with increased pregnancy likelihood.

Discussion

In this randomized, double-blind, placebo-controlled trial which followed HIV-1-uninfected men receiving TDF and FTC/TDF as PrEP for HIV-1 prevention and their HIV-1 female partners, we found similar pregnancy incidence and outcomes for couples receiving PrEP vs. placebo. These results suggest that the reproductive capacity of men was not attenuated by TDF-based PrEP. Importantly, in these HIV-1-serodiscordant couples who had access to effective contraception, pregnancy incidence (13% per year) was similar to the general population and to the incidence seen in the previous cohorts of HIV-1-serodiscordant couples. Whereas contraception was used at approximately half of the follow-up visits, fertility desires are strong and couples need to be counseled regarding risk-reduction strategies for peri-conception periods.

A limited number of studies among HIV-1-infected men have explored the potential impact of antiretroviral medications on male fertility, although these studies have assessed seminal parameters rather than direct measures of fertility. Some of these studies suggested decreased seminal quality among HIV-1-infected men receiving ART, with speculation for multiple classes of antiretrovirals, including nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors to potentially reduce

Table 2. Pregnancy incidence and outcomes among HIV-1-infected female partners of HIV-1-uninfected men randomized to pre-exposure prophylaxis or placebo.

	Total	TDF	FTC/TDF	Placebo	<i>P</i> -value vs. placebo
Number of pregnancies	583	192	193	198	
Number of women who became pregnant	541	181	177	183	
Pregnancy incidence (95% CI)	12.9 (11.9–14.0)	13.2 (11.4–15.1)	12.4 (10.7–14.1)	13.2 (11.4–15.0)	TDF: 0.91; FTC/TDF: 0.48
Outcome					
Live birth	460 (78.90)	152 (79.17)	162 (83.94)	146 (73.74)	TDF: 0.18; FTC/TDF: 0.039
Pregnancy loss	90 (15.44)	32 (16.67)	23 (11.92)	35 (17.68)	
Unknown	25 (4.29)	8 (4.17)	5 (2.59)	12 (6.06)	
Live births: gestational age at birth					
Term birth	425 (74.3)	142 (75.1)	148 (77.5)	135 (70.3)	TDF: 0.59; FTC/TDF: 0.63
Premature birth	22 (3.9)	7 (3.7)	9 (4.7)	6 (3.1)	
Unknown	4 (0.7)	0 (0.0)	3 (1.6)	1 (0.5)	
Pregnancy losses: gestational age at loss					
<20 weeks	60 (10.5)	20 (10.6)	15 (7.9)	25 (13.0)	TDF: 0.40; FTC/TDF: 0.45
20–36 weeks	23 (4.0)	10 (5.3)	7 (3.7)	6 (3.1)	
≥ 37 weeks	6 (1.1)	2 (1.1)	1 (0.5)	3 (1.6)	

CI, confidence interval; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate.

sperm quality [4,5]. Our findings suggest that the antiretroviral agents TDF and FTC do not compromise male fertility.

In multivariate analysis, we found that incident pregnancy was associated with younger age, sexual behavior unprotected by condoms, and lack of contraception. These findings are not surprising and similar correlates of pregnancy have been documented in other studies [11].

As part of the growing repertoire of HIV-1-prevention interventions, PrEP has been proposed for use during 'seasons' of high risk. One particular high-risk period is when HIV-1-serodiscordant couples are trying to conceive, when condom use will necessarily be reduced. Our results add to accumulating data that PrEP could be a useful and safe strategy for couples to decrease transmission risk during peri-conception periods, along with ART, if the infected partner is ready and eligible to initiate ART. Importantly, HIV-1-infected women who become pregnant should start and remain on ART for PMTCT of HIV-1 under the WHO-recommended option B+ regimen that is being implemented in many settings.

Our study had important strengths. To our knowledge, this is the first analysis that has made a direct assessment of male fertility with a conception outcome in relation to use of an antiretroviral medication. In addition, we assessed antiretroviral exposure and male fertility within a randomized, placebo-controlled trial allowing us to accumulate high-quality data under a study design that should substantially minimize bias. Another strength of our study is its large size: with the number of pregnancies that we observed, we had 90% power to detect a 20% reduction in pregnancy incidence due to PrEP use.

Our study had limitations. We did not collect information on seminal parameters, such as seminal volume, sperm count, morphology and motility, although it is known that conception is still possible with subtle changes or reduction in these parameters [12,13]. Importantly, the ultimate demonstration of fertility is achieving conception, which was the primary outcome for this analysis. In addition, we did not have data on the couples' fertility intentions, including the proportion trying to conceive. Furthermore, we did not have paternity data, but women rarely reported partners other than the study partner [6,10]. However, we would expect that differences in fertility intentions and instances of misclassified paternity would be balanced by randomization.

In conclusion, our findings suggest that TDF-based PrEP can prevent acquisition of HIV-1 infection in men without adverse effects on their fertility or the resultant pregnancy outcome. These reassuring findings are also relevant for HIV-1-infected men, as TDF is now part of

first-line ART for HIV-1-infected persons in many settings.

Acknowledgements

The authors thank the couples who participated in this study and the teams at the study sites for work on data collection and management. The authors acknowledge the Director, KEMRI, for support.

Author contributions: E.O.W. and J.M.B. conceived the study. R.H. performed the statistical analyses. E.O.W., R.H., and J.M.B. wrote the first draft of the manuscript. All authors contributed critical revisions to the analysis and interpretation and reviewed the final manuscript draft.

Partners PrEP Study Team: University of Washington Coordinating Center and Central Laboratories: Connie Celum (principal investigator, protocol co-chair), Jared M. Baeten (medical director, protocol co-chair), Deborah Donnell (protocol statistician), Robert W. Coombs, Lisa Frenkel, Craig W. Hendrix, Jairam Lingappa, M. Juliana McElrath.

Study sites and site principal investigators: Eldoret, Kenya (Moi University, Indiana University): Kenneth Fife, Edwin Were; Kabwohe, Uganda (Kabwohe Clinical Research Center): Elioda Tumwesigye; Jinja, Uganda (Makerere University, University of Washington): Patrick Ndase, Elly Katabira; Kampala, Uganda (Makerere University): Elly Katabira, Allan Ronald; Kisumu, Kenya (Kenya Medical Research Institute, University of California San Francisco): Elizabeth Bukusi, Craig Cohen; Mbale, Uganda (The AIDS Support Organization, CDC-Uganda): Jonathan Wangisi, James Campbell, Jordan Tappero; Nairobi, Kenya (University of Nairobi, University of Washington): James Kiari, Carey Farquhar, Grace John-Stewart; Kenya Medical Research Institute, Nairobi, Kenya: Nelly Rwamba Mugo; Tororo, Uganda (CDC-Uganda, The AIDS Support Organization): James Campbell, Jordan Tappero, Jonathan Wangisi.

Data management was provided by DF/Net Research, Inc. (Seattle, USA) and site laboratory oversight was provided by Contract Laboratory Services (University of the Witwatersrand, Johannesburg, South Africa).

Funding: The Bill and Melinda Gates Foundation (grant OPP47674) and the Eunice Kennedy Shriver National Institute of Child Health and Development (grants K99HD076679 and R21HD074439). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflicts of interest

There are no conflicts of interest.

References

1. Matthews LT, Baeten JM, Celum C, Bangsberg DR. **Periconception preexposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation.** *AIDS* 2010; **24**:1975–1982.
2. Taalo F, Berry M, Tsui A, Makanani B, Kafulafula G. **Fertility intentions of HIV-1 infected and uninfected women in Malawi: a longitudinal study.** *AIDS Behav* 2009; **13**: 20–27.
3. Kehl S, Weigel M, Muller D, Gentili M, Hornemann A, Sutterlin M. **HIV-infection and modern antiretroviral therapy impair sperm quality.** *Arch Gynecol Obstet* 2011; **284**:229–233.
4. van Leeuwen E, Wit FW, Repping S, Eeftinck Schattenkerk JK, Reiss P, van der Veen F, *et al.* **Effects of antiretroviral therapy on semen quality.** *AIDS* 2008; **22**:637–642.
5. Lambert-Niclot S, Poirot C, Tubiana R, Houssaini A, Soulie C, Dominguez S, *et al.* **Effect of antiretroviral drugs on the quality of semen.** *J Med Virol* 2011; **83**:1391–1394.
6. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, *et al.* **Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.** *N Engl J Med* 2012; **367**:399–410.
7. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, *et al.* **Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.** *N Engl J Med* 2012; **367**:423–434.
8. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, *et al.* **Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.** *N Engl J Med* 2010; **363**:2587–2599.
9. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, *et al.* **Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.** *Sci Transl Med* 2011; **3**:112re114.
10. Mujugira A, Baeten JM, Donnell D, Ndase P, Mugo NR, Barnes L, *et al.* **Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral preexposure prophylaxis for HIV-1 prevention.** *PLoS One* 2011; **6**:e25828.
11. The American Society for Reproductive Medicine. **Optimizing natural fertility: a committee opinion.** *Fertil Steril* 2013; **100**:631–637.
12. Kliesch S, Cooper TG. **Die Ejakulatdiagnostik.** *Der Urologe* 2008; **47**:1548–1554.
13. Slama R, Eustache F, Ducot B, Jensen TK, Jorgensen N, Horte A, *et al.* **Time to pregnancy and semen parameters: a cross-sectional study among fertile couples from four European cities.** *Hum Reprod* 2002; **17**:503–515.